XML 20 R6.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Operating activities:    
Net loss $ (18,879,077) $ (9,584,781)
Adjustments to reconcile net loss to net cash used in operating activities:    
Accretion of discount on marketable securities, net (708,019) (822,198)
Stock-based compensation expense 1,149,899 1,068,011
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 219,388 (698,545)
Deferred offering costs (269,331) 0
Accounts payable (162,221) 419,964
Accrued expenses and other current liabilities 882,253 486,384
Grant receivable 892,844 651,256
Net cash used in operating activities (16,874,264) (8,479,909)
Cash flows from investing activities:    
Purchase of marketable securities (20,776,519) (44,467,876)
Maturities of marketable securities 33,500,000 6,500,000
Net cash provided by (used in) investing activities 12,723,481 (37,967,876)
Cash flows from financing activities:    
Proceeds from the sale of common stock, prefunded warrants and common stock warrants, net of offering costs 0 46,398,606
Net cash provided by financing activities 4,588,687 46,398,606
Net increase (decrease) in cash and cash equivalents 437,904 (49,179)
Cash and cash equivalents at beginning of period 8,999,496 7,792,846
Cash and cash equivalents at end of period 9,437,400 7,743,667
Supplemental disclosure of non-cash investing and financing activities:    
Stock options granted in lieu of cash bonus 0 255,724
Cashless exercise of prefunded warrants 0 496
Open Market Sales Agreement [Member]    
Cash flows from financing activities:    
Sale of common stock under Open Market Sales Agreement, net of issuance costs $ 4,588,687 $ 0